Stiris Research Inc. announces the completion of Site Closeout Visits for its Phase III trial in Parkinson’s Disease
Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announced the completion of 84 Investigative Site closeout visits (COVs) for a global Phase III trial in Parkinson’s Disease (PD).
“We are very proud of our team’s accomplishment and for achieving the clients requested milestone. Our team completed 84 COVs in eight countries in just over three months. This is testament to our expertise and experience in global trial management,” said Kara Lee McWatters, Global Project Director at Stiris.
“The ability to close out a study of this size, in this many countries shows how well our team worked together and that strong communication both internally and with the Sponsor, can pull a series of activities together so seamlessly,” Amanda Carrera, Vice President.
Parkinson’s disease is the second most common neurodegenerative disorder and mainly affects the motor system. PD worsens and non-motor symptoms become more common. An estimated one million people will be living with PD in the United States by 2020, and approximately 60,000 Americans are diagnosed with PD each year (www.Parkinson.org).
About Stiris Research
Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.
For more information, please contact: